Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)
4.800
-0.020 (-0.41%)
Nov 11, 2026, 4:08 PM HKT
Jacobio Pharmaceuticals Group Employees
Jacobio Pharmaceuticals Group had 207 employees as of June 30, 2026. The number of employees increased by 140 or 208.96% since the number was reported on December 31, 2025. That makes Jacobio Pharmaceuticals Group the 26,521st largest employer in the world and 1,689th in Hong Kong.
Employees
207
Change
140
Growth
208.96%
Revenue / Employee
4.12M HKD
Profits / Employee
2.86M HKD
Market Cap
3.75B
Employees Chart
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 207 | 140 | 208.96% |
| Dec 31, 2025 | 67 | 5 | 8.06% |
| Dec 31, 2024 | 62 | -239 | -79.40% |
| Dec 31, 2023 | 301 | -2 | -0.66% |
| Dec 31, 2022 | 303 | 41 | 15.65% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Frontage Holdings | 1,800 |
| Ocumension Therapeutics | 608 |
| Shanghai Bao Pharmaceuticals | 364 |
| Qyuns Therapeutics | 353 |
| Mirxes Holding Company | 347 |
| Abbisko Cayman | 286 |
| Beijing Luzhu Biotechnology | 213 |
| TransThera Sciences (Nanjing) | 132 |
Jacobio Pharmaceuticals Group News
- 2 months ago - Jacobio Pharmaceuticals Group Earnings release: H1 2026 - Filings
- 2 months ago - Jacobio Pharmaceuticals Group Quarterly report: H1 2026 - Filings
- 8 months ago - Jacobio Pharmaceuticals Group Earnings release: H2 2025 - Filings
- 8 months ago - Jacobio Pharmaceuticals Group Annual report: H2 2025 - Filings
- 10 months ago - Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73 - PRNewsWire
- 1 year ago - Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline - PRNewsWire
- 1 year ago - Jacobio Pharma Announces 2025 Interim Results - PRNewsWire
- 1 year ago - Jacobio's IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted - PRNewsWire